Welcome to our dedicated page for Cvs Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on Cvs Health stock.
CVS Health Corporation operates an integrated health care model that combines retail pharmacy, pharmacy benefit management, health insurance, medical clinics, specialty and mail pharmacy support, and related consumer health services. Recurring company news includes quarterly results and guidance, segment performance across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, and capital returns through common-stock dividends.
Updates also cover CVS Caremark formulary decisions, biosimilar adoption, Aetna prior authorization and plan-administration initiatives, community health investments by the CVS Health Foundation, and developments involving Omnicare, the company's long-term care pharmacy subsidiary.
CVS Health has announced cash tender offers for certain outstanding notes, including any and all of its 4.100% Senior Notes due 2025 and several other series of notes under a Maximum Tender Offer. The total maximum purchase price across both tenders will not exceed $2 billion. The company plans to fund these purchases using proceeds from a future issuance of subordinated debt securities.
The Any and All Notes tender expires on December 6, 2024, while the Maximum Tender Offer has an Early Tender Date of December 13, 2024, and final expiration on December 31, 2024. The purpose is to retire a portion of CVS Health's outstanding indebtedness.
CVS Health has appointed Dr. Sreekanth Chaguturu as President of Health Care Delivery, while maintaining his current role as Executive Vice President and Chief Medical Officer. He replaces Mike Pykosz, who is leaving the company. The company reported significant growth in its Health Care Delivery business, with Aetna members served by Signify nearly doubling year-over-year and Oak Street's at-risk membership increasing by 32%. The number of Aetna members enrolled at Oak Street has approximately quadrupled since the acquisition. Dr. Chaguturu will focus on connecting care delivery across Oak Street Health clinics, MinuteClinic locations, and Signify Health's home services.
CVS Health has appointed four new members to its Board of Directors: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman, following productive discussions with Glenview Capital Management. The appointments aim to enhance financial and operational performance through new thinking and industry experience. Norwalk will join the Health Services Committee, Sansone the Audit Committee, and Shulman the Management Planning and Development Committee. The Board now consists of 16 members. CVS Health and Glenview have entered into a confidentiality agreement with customary standstill provisions.
CVS Health (NYSE: CVS) announced that Chief Financial Officer Tom Cowhey will participate in a fireside chat with investors at the Wolfe 2024 Healthcare Conference on November 19, 2024, at approximately 10:20 am ET. The event will be available via audio webcast on the Investor Relations section of the CVS Health website at investors.cvshealth.com, where it will remain accessible for one year.
CVS Health announced key leadership appointments, with Prem Shah named as Group President and Steve Nelson as President of Aetna, both reporting to CEO David Joyner. Shah, who joined CVS in 2013, will oversee operational performance and integrated value creation across CVS Caremark, CVS Pharmacy, and Health Care Delivery businesses. Nelson, former CEO of ChenMed and UnitedHealthcare, brings extensive managed care experience to lead Aetna. These appointments aim to enhance the company's integrated business model and improve financial and operational performance.
CVS Health reported Q3 2024 results with total revenues increasing 6.3% to $95.4 billion. However, GAAP diluted EPS dropped to $0.07 from $1.75, and Adjusted EPS fell to $1.09 from $2.21 year-over-year. The decline was primarily due to challenges in the Health Care Benefits segment, including a $1.1 billion premium deficiency reserve charge. The company recorded restructuring charges of approximately $1.2 billion, including store closures and workforce optimization. The Health Services and Pharmacy & Consumer Wellness segments showed strong performance, with prescription volume up 6.0%. Year-to-date cash flow from operations was $7.2 billion.
CVS Health Foundation announced $1.5 million in new Health Zones funding to support healthcare access in Atlanta, partnering with Good Samaritan Health Center, Open Hand Atlanta, and Uber Health. The initiative focuses on addressing diabetes and hypertension through comprehensive clinical services, transportation, and medically tailored meals.
Initial six-month results show significant improvements: 53% of diabetic participants showed improved A1c levels, 56% of hypertensive participants demonstrated better blood pressure control, and medication adherence improved with only 13.3% of participants skipping medication compared to 36.4% previously. The program has helped 1,277 patients with chronic disease support and provided 40 participants with access to nutrition education and meal services.
CVS Health announced the appointment of David Joyner as President and CEO, effective October 17, replacing Karen Lynch. Roger Farah was named Executive Chairman of the Board. Joyner, with 37 years of healthcare experience, previously served as executive vice president of CVS Health and president of CVS Caremark.
The company provided preliminary guidance for Q3 2024, projecting GAAP diluted EPS of $0.03 to $0.08 and Adjusted EPS of $1.05 to $1.10. This includes charges of approximately $1.1 billion for premium deficiency reserves, primarily related to Medicare and Individual Exchange businesses, lowering Q3 2024 Adjusted EPS by $0.63. A restructuring charge of about $1.2 billion is also expected, related to store closures and cost reduction actions.
CVS Health reported continued elevated medical cost trends, with an expected Medical Benefit Ratio of approximately 95.2% for Q3. The company plans to provide further updates on its Q3 2024 earnings call scheduled for November 6, 2024.
Aetna, a CVS Health company (NYSE: CVS), has introduced SimplePay Health, an innovative health plan for self-insured clients. This alternative offering aims to reduce health care costs, improve health outcomes, and simplify the health care experience. Key features include:
- Price certainty before visits or treatments
- Copay-only system for all covered medical and pharmacy services
- Bundled payments for end-to-end services
- Provider search app ranking quality and efficiency
- Simple monthly statements summarizing all claims
- Zero percent interest payment options
SimplePay Health has demonstrated a 60% increase in use of top-quality providers and 12% total cost of care savings for employers and members. The plan offers no deductibles, no co-insurance, and zero out-of-pocket costs at time of service, aiming to create a seamless, high-quality health care delivery experience.
CVS Health has released The Rx Report, exploring the transformation of community pharmacy and opportunities to meet consumer expectations, support the workforce, and advance the pharmacy model. Key findings from a CVS Health/Morning Consult survey reveal:
- 76% of consumers have at least one active prescription
- 81% trust their local pharmacist
- 83% value their pharmacist's recommendations
- 70% prefer in-person interactions over digital-only experiences
The report highlights challenges in the industry, including the need for a new reimbursement model. CVS Pharmacy is introducing CVS CostVantage, a transparent formula based on drug cost plus a dispensing fee. The report also emphasizes the importance of supporting pharmacy teams and inspiring the next generation of pharmacists, as enrollment in pharmacy schools has declined by 29% in the last five years.